[go: up one dir, main page]

CN108699060A - 结合有脂肪酸的恩替卡韦衍生化合物及其药学用途 - Google Patents

结合有脂肪酸的恩替卡韦衍生化合物及其药学用途 Download PDF

Info

Publication number
CN108699060A
CN108699060A CN201780012633.6A CN201780012633A CN108699060A CN 108699060 A CN108699060 A CN 108699060A CN 201780012633 A CN201780012633 A CN 201780012633A CN 108699060 A CN108699060 A CN 108699060A
Authority
CN
China
Prior art keywords
oxo
amino
hydroxyl
purine
entecavir
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201780012633.6A
Other languages
English (en)
Chinese (zh)
Inventor
姜明柱
韩荣泽
李大路
扈铭眞
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Industry Academic Cooperation Foundation of Dankook University
Original Assignee
Industry Academic Cooperation Foundation of Dankook University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Industry Academic Cooperation Foundation of Dankook University filed Critical Industry Academic Cooperation Foundation of Dankook University
Publication of CN108699060A publication Critical patent/CN108699060A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
    • C07D473/18—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 one oxygen and one nitrogen atom, e.g. guanine

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CN201780012633.6A 2016-10-07 2017-09-29 结合有脂肪酸的恩替卡韦衍生化合物及其药学用途 Pending CN108699060A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
KR1020160129647A KR101996229B1 (ko) 2016-10-07 2016-10-07 지방산이 결합된 엔테카비어 유도체 화합물 및 이의 약학적 용도
KR10-2016-0129647 2016-10-07
PCT/KR2017/011022 WO2018066947A1 (ko) 2016-10-07 2017-09-29 지방산이 결합된 엔테카비어 유도체 화합물 및 이의 약학적 용도

Publications (1)

Publication Number Publication Date
CN108699060A true CN108699060A (zh) 2018-10-23

Family

ID=61832028

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201780012633.6A Pending CN108699060A (zh) 2016-10-07 2017-09-29 结合有脂肪酸的恩替卡韦衍生化合物及其药学用途

Country Status (3)

Country Link
KR (1) KR101996229B1 (ko)
CN (1) CN108699060A (ko)
WO (1) WO2018066947A1 (ko)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN109575026A (zh) * 2017-09-29 2019-04-05 广州市恒诺康医药科技有限公司 长效恩替卡韦前药及其制备方法和应用
CN114105987A (zh) * 2020-08-26 2022-03-01 上海博志研新药物技术有限公司 恩替卡韦药用盐及其制备方法、药物组合物和应用

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101096370A (zh) * 2006-06-29 2008-01-02 朱靖华 缬氨酸恩替卡韦及其制备方法和应用
US20090088397A1 (en) * 2006-05-04 2009-04-02 Andrea Cuconati Inhibitors of secretion of hepatitis b virus antigens for treatment of a chronic hepatitis virus
WO2013090420A2 (en) * 2011-12-12 2013-06-20 Catabasis Pharmaceuticals, Inc. Fatty acid antiviral conjugates and their uses
CN103804417A (zh) * 2012-11-13 2014-05-21 北京美倍他药物研究有限公司 抗乙肝病毒药物
CN105585569A (zh) * 2015-12-28 2016-05-18 正大天晴药业集团股份有限公司 一种恩替卡韦脂肪酸衍生物及其药物组合物

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101633292B1 (ko) 2014-02-25 2016-06-24 동아에스티 주식회사 용법이 개선된 엔테카비어를 함유하는 약학적 조성물

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090088397A1 (en) * 2006-05-04 2009-04-02 Andrea Cuconati Inhibitors of secretion of hepatitis b virus antigens for treatment of a chronic hepatitis virus
CN101096370A (zh) * 2006-06-29 2008-01-02 朱靖华 缬氨酸恩替卡韦及其制备方法和应用
WO2013090420A2 (en) * 2011-12-12 2013-06-20 Catabasis Pharmaceuticals, Inc. Fatty acid antiviral conjugates and their uses
CN103804417A (zh) * 2012-11-13 2014-05-21 北京美倍他药物研究有限公司 抗乙肝病毒药物
CN105585569A (zh) * 2015-12-28 2016-05-18 正大天晴药业集团股份有限公司 一种恩替卡韦脂肪酸衍生物及其药物组合物

Cited By (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN109575026A (zh) * 2017-09-29 2019-04-05 广州市恒诺康医药科技有限公司 长效恩替卡韦前药及其制备方法和应用
CN112358481A (zh) * 2017-09-29 2021-02-12 广州市恒诺康医药科技有限公司 长效恩替卡韦前药及其制备方法和应用
CN112358481B (zh) * 2017-09-29 2022-02-22 广州市恒诺康医药科技有限公司 长效恩替卡韦前药及其制备方法和应用
CN114105987A (zh) * 2020-08-26 2022-03-01 上海博志研新药物技术有限公司 恩替卡韦药用盐及其制备方法、药物组合物和应用
WO2022042641A1 (zh) * 2020-08-26 2022-03-03 上海博志研新药物技术有限公司 恩替卡韦药用盐及其制备方法、药物组合物和应用
CN114105987B (zh) * 2020-08-26 2022-12-27 上海博志研新药物技术有限公司 恩替卡韦药用盐及其制备方法、药物组合物和应用
CN115925710A (zh) * 2020-08-26 2023-04-07 上海博志研新药物技术有限公司 恩替卡韦药用盐及其制备方法、药物组合物和应用
CN115925710B (zh) * 2020-08-26 2025-08-08 上海博志研新药物研究有限公司 恩替卡韦药用盐及其制备方法、药物组合物和应用

Also Published As

Publication number Publication date
WO2018066947A1 (ko) 2018-04-12
BR112018017005A2 (pt) 2018-12-26
KR101996229B1 (ko) 2019-07-04
KR20180038697A (ko) 2018-04-17

Similar Documents

Publication Publication Date Title
JP5596680B2 (ja) 経口抗がん製剤
CN111295372B (zh) 硝羟喹啉前药及其用途
US20160038454A1 (en) Intravenous formulations of triptolide compounds as immunomodulators and anticancer agents
US20150119388A1 (en) Novel pro- and codrug derivatives for nanoparticle delivery of select anticancer agents formed using rapidly cleavable phenolic ester bridges
CN101080417B (zh) 吉西他滨的酰胺前体药物、其组合物以及应用
Ho et al. Microsuspension of fatty acid esters of entecavir for parenteral sustained delivery
CN111902394A (zh) 与特异性促炎症消退介质的盐有关的组合物和方法
WO2018071679A1 (en) N-acylethanolamide derivatives and uses thereof
CN113336768B (zh) 一种多靶点酪氨酸激酶抑制剂
TW202308993A (zh) 色胺及苯乙胺致幻劑之脂質前藥及其用途
CN115160227A (zh) R-或s-2-(1-乙酰氧正戊基)苯甲酸与4-氟-依达拉奉的杂合物及其制备与应用
CN107001302B (zh) 一类水溶性紫杉烷类衍生物及其用途
CN108699060A (zh) 结合有脂肪酸的恩替卡韦衍生化合物及其药学用途
CN105585569B (zh) 一种恩替卡韦脂肪酸衍生物及其药物组合物
US11292811B2 (en) Long-acting prodrugs of entecavir, preparing methods and uses thereof
CN116178373A (zh) 非甾体抗炎药和gs-441524的二联体化合物及其制备方法与用途
WO2022190626A1 (ja) Ｓｎ－３８誘導体、当該誘導体を含むナノ粒子、医薬及び当該ナノ粒子の製造方法
CN108774264A (zh) 卵磷脂类似物、制备方法及用途
CN104341481A (zh) 一种磺酰胺化合物的合成和应用
WO2023134682A1 (zh) 一种光学活性2-羟基四氢噻吩并吡啶类衍生物及其制备方法和用途
BR112018017005B1 (pt) Composto derivado de entecavir e composição farmacêutica para prevenir ou tratar hepatite b
CN117327028B (zh) 吩噻嗪类衍生物、药物组合物及其在治疗棘球蚴病中的用途
CN106317168A (zh) 10-甲氧基喜树碱酯化衍生物、制备方法和用途
CN108558869B (zh) 用于治疗肝癌的化合物及其制剂
CN118063413A (zh) 一种卡巴他赛类甘油三酯前药及其制备方法和应用

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
RJ01 Rejection of invention patent application after publication

Application publication date: 20181023

RJ01 Rejection of invention patent application after publication